Clinical Trial

Multi-Site STARgraft (10401) Trial

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a multi-site, single-blind with parallel group, randomized controlled trial of Healionics STARgraft (10401) vascular graft for hemodialysis access compared with a market-leading commercially available ePTFE vascular graft (Gore Propaten Vascular Graft).
Protocol Amendment History 2 changes
notable Enrollment increased: 75 -> 111 participants 2026-08-14
notable Trial sites expanded: 1 -> 7 locations 2026-08-14
Trial Details
NCT Number NCT07557862
Lead Sponsor Healionics Corporation
Conditions End Stage Renal Disease (ESRD)
Enrollment 111 participants
Start Date 2026-10
Primary Completion 2027-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-13